133 related articles for article (PubMed ID: 38686876)
1. Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Lorber J; Niederau C; Carwile JL; Oliveira-Dos-Santos A; Perichon MG; Uslu Cil S; Kishnani PS
Am J Hematol; 2024 Apr; ():. PubMed ID: 38686876
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Kishnani P; Niederau C; Underhill LH; McClain MR
Am J Hematol; 2020 Sep; 95(9):1038-1046. PubMed ID: 32438452
[TBL] [Abstract][Full Text] [Related]
3. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
[TBL] [Abstract][Full Text] [Related]
4. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
[TBL] [Abstract][Full Text] [Related]
6. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Goker-Alpan O; Watman N; El-Beshlawy A; Kishnani PS; Pedroso ML; Gaemers SJM; Tayag R; Peterschmitt MJ
Blood; 2017 Apr; 129(17):2375-2383. PubMed ID: 28167660
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Ibrahim J; Underhill LH; Taylor JS; Angell J; Peterschmitt MJ
Mol Genet Metab Rep; 2016 Sep; 8():17-9. PubMed ID: 27408819
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
[TBL] [Abstract][Full Text] [Related]
10. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
[TBL] [Abstract][Full Text] [Related]
12. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
14. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
[TBL] [Abstract][Full Text] [Related]
16. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
17. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
18. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
19. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
[TBL] [Abstract][Full Text] [Related]
20. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.
Kamath RS; Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Aguzzi R; Puga AC; Norfleet AM; Peterschmitt MJ; Rosenthal DI
Skeletal Radiol; 2014 Oct; 43(10):1353-60. PubMed ID: 24816856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]